EMIG Conducts a Member's Investment Intentions Survey
The Ethical Medicines Interest Group (EMIG) recently surveyed members on 2023-member investment intentions related to the VPAS Rebate Level.
Read on to see the results of EMIG’s recent member survey into the 2023 VPAS rate and its implications. EMIG meets regularly with DHSC, NICE and NHSE-I to review progress of the VPAS, including rebate levels and adoption and uptake mechanisms. They are a member of the NICE Review of Methods and Process Working Group and have supported the creation of the NHSE-I Commercial Framework.
During the negotiations on the current VPAS, EMIG argued for industry rebates to be paid into an Innovative Medicines Fund to underwrite adoption of innovation by the NHS. Although not part of the VPAS, the idea for an Innovative Medicines Fund has since been adopted by Government and is under development.
50% of respondents said that they will reduce supply of medicines to the UK in 2023 and a further 40% are discussing a reduction
86% of respondents felt that DHSC’s 2019 VPAS 2% growth cap ‘affordability mechanism’ was not providing certainty and stability for their business
75% of respondents suggested that the predicted 2023 VPAS rebate would lead to a significant reduction of investment in UK Clinical Research, with over 75% of respondents predicting a 10-20%+ decrease
85% of respondents stated that one or more medicines would likely be moved down the launch sequence, with 10% stating that 5 or more medicines would be affected.
No respondents felt that the ‘access, uptake and outcomes’ commitments have been fully meaningfully delivered.
It is clear that the model that underpins VPAS is delivering unexpected and difficult outcomes for the sector.